Can-Fite BioPharma Ltd. (NYSE:CANF) has a beta value of 0 and has seen 617,573 shares traded in the last trading session. The company, currently valued at $26.59 Million, closed the last trade at $1.82 per share which meant it lost -$0.33 on the day or -15.59% during that session. The CANF stock price is -171.98% off its 52-week high price of $4.95 and 40.66% above the 52-week low of $1.08. If we look at the company’s 10-day average daily trading volume, we find that it stood at 530.08 Million shares traded. The 3-month trading volume is 837.89 Million shares.
The consensus among analysts is that Can-Fite BioPharma Ltd. (CANF) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.4.
Can-Fite BioPharma Ltd. (NYSE:CANF) trade information
Despite being -15.59% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Oct 15 when the CANF stock price touched $2.22 or saw a rise of 18.06%. Year-to-date, Can-Fite BioPharma Ltd. shares have moved -44.88%, while the 5-day performance has seen it change 1.06%. Over the past 30 days, the shares of Can-Fite BioPharma Ltd. (NYSE:CANF) have changed -2.73%. Short interest in the company has seen 333.1 Million shares shorted with days to cover at 0.4.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 174.73% from current levels. The projected low price target is $5 while the price target rests at a high of $5. In that case, then, we find that the current price level is +174.73% off the targeted high while a plunge would see the stock lose 174.73% from current levels.
Can-Fite BioPharma Ltd. (CANF) estimates and forecasts
2 analysts offering their estimates for the company have set an average revenue estimate of $250Million for the current quarter. 2 have an estimated revenue figure of $250Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $1.15 Million and $192Million respectively for this quarter and the next, and analysts expect sales will grow by -78.3% for the current quarter and 30.2% for the next.
Earnings growth for 2020 is a modest +11.5%.